Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANK-302
- Development stage
- Preclinical
- Lead developer
- Ankyra Therapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
ANK-302 is an investigational bi-agonist immunotherapy being developed by Ankyra Therapeutics for the treatment of solid tumors. It is designed to simultaneously engage the CD28 co-stimulatory pathway and the Interleukin-2 (IL-2) signaling pathway. By dual-targeting these mechanisms, ANK-302 aims to enhance the activation, proliferation, and persistence of tumor-reactive T cells within the tumor microenvironment. This approach is intended to provide potent anti-tumor activity while potentially improving the safety profile compared to systemic cytokine therapies by localizing the immune stimulation. As of early 2024, the program is in the discovery stage of development.
02
Targets
CD28 (Cluster of Differentiation 28)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on ANK-302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANK-302.